Drug Database · Clinicians

Clonidine

Brands (29) Catapin, Catamed, Catapres…Show all

US brand (reference label): clonidine hydrochloride; not a Philippine-registered brand.

Antihypertensive (imidazoline receptor agonist); Antihypertensive (imidazoline receptor antagonist); and others PH FDA category

Rx · Prescription drug49 PH productsPNF-listedPhilHealth GAMOTVAT-exempt (some products)
Dispensing: Prescription (Rx) Last updated: Audience: Licensed health professionals
Label text on this page: US FDA-approved label via DailyMed/openFDA, set ID 88a8db46-0fc9-48cd-b7cc-ac9c9cdea100, version date September 30, 2026 (clonidine hydrochloride · Alembic Pharmaceuticals Limited). Reproduced verbatim. Philippine-approved indications and doses may differ: check the PH package insert.

Use: Labeled indications

  • INDICATIONS AND USAGE Clonidine hydrochloride is indicated in the treatment of hypertension.
US FDA label
Full indications and usage US FDA label

INDICATIONS AND USAGE Clonidine hydrochloride is indicated in the treatment of hypertension. Clonidine hydrochloride may be employed alone or concomitantly with other antihypertensive agents.

Contraindications

CONTRAINDICATIONS Clonidine hydrochloride tablets USP should not be used in patients with known hypersensitivity to clonidine (see PRECAUTIONS).

US FDA label

Dosing: Adult

Dosage and administration (US label) US FDA label

DOSAGE AND ADMINISTRATION Adults The dose of clonidine hydrochloride USP must be adjusted according to the patient's individual blood pressure response. The following is a general guide to its administration. Initial Dose 0.1 mg tablet twice daily (morning and bedtime). Elderly patients may benefit from a lower initial dose.

Maintenance Dose Further increments of 0.1 mg per day may be made at weekly intervals if necessary until the desired response is achieved. Taking the larger portion of the oral daily dose at bedtime may minimize transient adjustment effects of dry mouth and drowsiness. The therapeutic doses most commonly employed have ranged from 0.2 mg to 0.6 mg per day given in divided doses.

Studies have indicated that 2.4 mg is the maximum effective daily dose, but doses as high as this have rarely been employed. Renal Impairment Patients with renal impairment may benefit from a lower initial dose. Patients should be carefully monitored.Since only a minimal amount of clonidine is removed during routine hemodialysis, there is no need to give supplemental clonidine followingdialysis.

Dosing: Altered kidney function

From the US FDA label · Renal impairment (dosage and administration)

Renal Impairment Patients with renal impairment may benefit from a lower initial dose. Patients should be carefully monitored.Since only a minimal amount of clonidine is removed during routine hemodialysis, there is no need to give supplemental clonidine followingdialysis.

Kidney-specific guidance from renalcarematters.com: in preparation.

Dosing: Pediatric

Pediatric use (US label) US FDA label

Pediatric Use Safety and effectiveness in pediatric patients have not been established in adequate and well-controlled trials (see WARNINGS, Withdrawal).

Dosage forms

Philippines

  • Tablet: 75 mcg, 150 mcg
  • Solution for injection: 150 mcg/mL

Registered products in the Philippines

49 products registered with the Food and Drug Administration (FDA) Philippines list Clonidine as the generic name (including products registered under a variant spelling). Registration status changes; confirm a product's current status on the FDA portal before relying on it.

Also registered under: Clonidine hydrocloride (1 product). Products registered under these spellings are included in the table and marked.

Verify on PH FDA portal

All registered products49
Philippine FDA-registered products for Clonidine
Package insert
AlphapresClonidine (as Hydrochloride)
75 mcg TabletAlu/Clear PVDC Blister Pack x 10's (Box of 100's)
RxVAT-exempt
Lloyd Laboratories, Inc.Philippines
Trader: Medlink Pharma Phils., Inc.
DR-XY40860
May 10, 2027
CataclonClonidine Hydrochloride
75 mcg TabletAlu/Clear PVDC Blister Pack x 10's (Box of 100's)
RxVAT-exempt
Lloyd Laboratories, Inc.Philippines
Trader: Corbridge Group Phils., Inc.
DR-XY40812
Apr 3, 2028
Cataclon 150Clonidine Hydrochloride
150 mcg TabletAlu/Clear PVC Blister pack x 20's (Box of 100's)
RxVAT-exempt
Sapphire Lifesciences Pvt. Ltd.India
Corbridge Group Phils., Inc.Importer: Nelpa Lifesciences, Inc.
DRP-12494-01
Aug 19, 2027
CatamedClonidine Hydrochloride
150 mcg TabletAlu/Clear PVDC Blister Pack x 10's (Box of 100's)
RxVAT-exempt
Lloyd Laboratories, Inc.Philippines
Trader: Ultramed Pharma, Inc.
DR-XY42851
Oct 18, 2028
CatamedClonidine Hydrochloride
75 mcg TabletAlu/Clear PVDC Blister Pack x 10's Box of 100's
RxVAT-exempt
Lloyd Laboratories, Inc.Philippines
Trader: Ultramed Pharma, Inc.
DRP-6756
Oct 23, 2028
CatapinClonidine Hydrochloride
150 mcg/mL Solution for Injection (IV)USP Type I Amber Glass Ampoule x 1mL (Box of 10's)
RxVAT-exempt
Ciron Drugs & Pharmaceuticals Pvt. Ltd.India
Phil Pharmawealth, Inc.Trader: Oboi Laboratories
DRP-6580
Feb 1, 2032
CatapinClonidine hydrochloride
75 mcg TabletAlu/Clear PVC Blister Pack x 20's (Box of 100's)
RxVAT-exempt
Sai Parenterals Ltd.TSIIC Industrial Park Hyderabad-Warangal Highway Bhongir Telangana 508116 India
Phil. Pharmawealth, Inc.Importer: Nelpa Lifesciences, Inc.
DRP-12495-02
Jul 2, 2030
CatapinClonidine Hydrochloride
75 mcg TabletClear PVDC/Alu Blister Pack x 10's (Box of 100's)
RxVAT-exempt
Lloyd Laboratories, Inc.Philippines
Phil. Pharmawealth, Inc.Trader: Gamot Philippines, Inc.
DRP-6744
Feb 7, 2031
CatapresClonidine Hydrochloride
150 mcg TabletAluminum/PVC/PVDC Foil Blister Strip x 10’s Box of 100's
RxVAT-exempt
Delpharm ReimsFrance
Importer: Metro Drug, Inc.
DRP-7888
Feb 21, 2030
CatapresClonidine Hydrochloride
75 mcg TabletAluminum/PVC/PVDC foil blister strip x 10’s (Box of 100's)
RxVAT-exempt
Delpharm ReimsFrance
Importer: Metro Drug, Inc.
DRP-7887
Feb 21, 2030
ChlonbitechClonidine hydrochloride
150 mcg TabletAlu/Clear PVC blister pack x 20's (Box of 100's)
RxVAT-exempt
Sapphire Lifesciences Pvt. Ltd.India
Ambitech Biopharmaceuticals Inc.Importer: Nelpa Lifesciences, Inc.
DRP-12494-03
Aug 19, 2027
CLOBASEClonidine Hydrochloride
150 mcg TabletAlu/PVC/PvDC Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Base Medico Private LimitedIndia
AMB HK Enterprises, Inc.
DRP-19060
Oct 22, 2031
ClodinClonidine Hydrochloride
150mcg TabletAlu/Clear PVC Blister pack x 20's Box of 100's
RxVAT-exempt
Drugmaker's Laboratories, Inc.Philippines
—
DRP-5247
Dec 6, 2027
ClodinClonidine Hydrochloride
75 mcg TabletAlu/PVC Blister Pack x 20's (Box of 100's)
RxVAT-exempt
Drugmaker’s Laboratories Inc.Philippines
—
DRP-6787
Jul 19, 2028
ClodroxineClonidine hydrochloride
75 mcg TabletAlu/Clear PVC blister pack x 20's (Box of 100's)
RxVAT-exempt
Sapphire Lifesciences Pvt. Ltd.India
Ambitech Biopharmaceuticals Inc.Importer: Nelpa Lifesciences, Inc.
DRP-12495-01
Aug 19, 2027
ClonigardClonidine
75 mcg TabletAlu/Clear PVDC Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Lloyd Laboratories, Inc.Philippines
—
DRP-7774
Mar 19, 2030
ClonigenClonidine (as Hydrochloride)
150 mcg TabletAlu/Clear PVDC Blister Pack x 10's (Box of 100's)
RxVAT-exempt
Lloyd Laboratories, Inc.Philippines
Trader: Innogen Pharmaceuticals, Inc.
DRP-6315
Mar 2, 2027
ClonigenClonidine
75 mcg TabletAlu/Clear PVDC Blister Pack x 10's (Box of 100's)
RxVAT-exempt
Lloyd Laboratories, Inc.Philippines
Trader: Innogen Pharmaceuticals, Inc.
DRP-6300
Feb 16, 2028
ClonilifeClonidine Hydrochloride
150 mcg TabletAlu/Clear PVC Blister Pack x 10's (Box of 100's) and x 20's (Box of 100's)
RxVAT-exempt
Flourish PharmaIndia
Biophil Medical Equipment and Supplies Trading
DRP-17486
Jan 12, 2031
ClonilifeClonidine Hydrochloride
75 mcg TabletAlu/Clear PVC Blister Pack x 10's (Box of 100's) and x 20's (Box of 100's)
RxVAT-exempt
Flourish PharmaIndia
Biophil Medical Equipment and Supplies Trading
DRP-17485
Jan 12, 2031
ClonimedClonidine (as Hydrochloride)
150 mcg TabletAlu/Clear PVDC Blister Pack x 10's (Box of 100's)
RxVAT-exempt
Lloyd Laboratories, Inc.Philippines
TGP Pharma Inc.Trader: D.B. Manix International, Inc.
DR-XY40732
Mar 9, 2027
CloninClonidine Hydrochloride
150 mcg TabletAlu/PVDC Blister Pack x 10's Box of 30's
RxVAT-exempt
LLOYD LABORATORIES, INC.Philippines
Trader: VITALINK HEALTH PRODUCTS, INC.
DR-XY44304
Mar 19, 2030
CloninClonidine hydrochloride
75 mcg TabletAlu/PVDC Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Lloyd Laboratories, Inc.Philippines
Trader: Vitalink Health Products, Inc.
DR-XY44225
Feb 23, 2030
ClonipressClonidine Hydrochloride
150 mcg TabletAlu/PVC Blister Pack x 20's (Box of 100's)
RxVAT-exempt
Amherst Laboratories, Inc.Philippines
Trader: UNILAB, INC.
DRP-2046
Jun 22, 2027
ClonipressClonidine Hydrochloride
75 mcg TabletAlu/PVC Blister Pack x 20's (Box of 100's)
RxVAT-exempt
Amherst Laboratories, Inc.Philippines
Trader: UNILAB, INC.
DRP-1868
Jun 22, 2027
Clonisaph-150Clonidine Hydrochloride
150 mcg TabletAlu/Clear PVC Blister Pack of 20's (Box of 100's) Alu/Clear PVC Blister Pack of 10's (Box of 100's)
RxVAT-exempt
Sai Parenterals Ltd.India
Nelpa Lifesciences, Inc.
DRP-12494
Sep 8, 2031
Clonisaph-75Clonidine hydrochloride
75 mcg TabletAlu/Clear PVC Blister Pack x 20's (Box of 100's)
RxVAT-exempt
Sai Parenterals Ltd.India
Nelpa Lifesciences Inc.
DRP-12495
Jul 2, 2030
Clonisaph-InfClonidine hydrochloride
150mcg/mL Solution For Injection (Im/Iv)USP Type I Clear Glass ampoule x 1 mL (Box of 5's and 10's)
RxVAT-exempt
Kilitch Drugs (India) Ltd.India
Nelpa Lifesciences, Inc.Trader: Sapphire Lifesciences Pvt. Ltd.
FDA-0592800
Jun 8, 2028
CloniseaClonidine Hydrochloride
150 mcg / mL Solution for Injection (I.V.)1 mL Type I clear glass ampoule with White Ring on Neck (Box of 10's)
RxVAT-exempt
Kwality Pharmaceuticals Ltd.India
Seapharma International, Inc.Importer: Pharma-Surrey International, Inc.
DRP-14325-01
Aug 23, 2028
ClonisurClonidine Hydrochloride
150mcg/mL Solution for Injection (I.V.)1 mL Type I clear glass ampoule with White Ring on Neck (Box of 10's)
RxVAT-exempt
Kwality Pharmaceuticals Ltd.India
Pharma Surrey Internationl, Inc.
DRP-14325
Aug 23, 2028
ClopresClonidine Hydrochloride
75 mcg TabletAlu/Clear PVDC Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Lloyd Laboratories, Inc.Philippines
Trader: Westfield Pharmaceuticals, Inc.
DRP-10385
Feb 23, 2030
ClotapressClonidine Hydrochloride
150 mcg/mL Solution for Injection (IM/IV)1 mL USP Type I Clear Glass Ampoule (Box of 10's)
RxVAT-exempt
Armein Pharmaceuticals Pvt. Ltd.India
Philgen Pharmaceuticals, Inc.
DRP 15354
Jul 1, 2029
ControlClonidine Hydrochloride
150 mcg TabletAlu-PVC/PVDC Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Globela Pharma Private LimitedIndia
AMB HK Enterprises Inc.
DRP-12536
Aug 30, 2032
CyclodineClonidine Hydrochloride
150 mcg/mL Solution for Injection (IM/IV)Clear Glass Ampoule x 1 mL (Box of 5's)
RxVAT-exempt
Yung Shin Pharm. Ind. Co., Ltd. - Taichung Youth FactoryTaiwan
Dynasty PharmaceuticalsImporter: Yung Shin (Philippines), Inc.
DRP-1146-01
Feb 8, 2032
Lonid 75Clonidine hydroclorideVariant spelling
75 mcg TabletAlu/Clear PVC Blister Pack x 7's (Box of 28's); Alu/clear PVC Blister Pack x 10's (Box of 10's)
Rx
Bafna Pharmaceuticals LimitedIndia
MedEthix Inc.
DRP-14355
Aug 31, 2030
MelzinClonidine Hydrochloride
150mcg/mL Solution for Injection (I.M./I.V.)Clear Glass Ampoule x 1mL (Box of 5's)
RxVAT-exempt
Yung Shin Pharm. Ind. Co., Ltd. - Taichung Youth FactoryTaiwan
Yung Shin (Philippines), Inc.
DRP-1146
Mar 7, 2031
NoneClonidine Hydrochloride
150 mcg TabletAlu/PVC Blister Pack x 20's (Box of 100's)
RxVAT-exempt
Amherst Laboratories, Inc.Philippines
RiteMED Phils., Inc.Trader: UNILAB, Inc.
DRP-2046-01
Jun 22, 2027
NoneClonidine Hydrochloride
150 mcg TabletAlu/Clear PVC Blister pack x 20's (Box of 100's)
RxVAT-exempt
Drugmaker's Laboratories, Inc.Philippines
TGP Pharma Inc.
DRP-5247-2
Dec 6, 2027
NoneClonidine (as hydrochloride)
150 mcg TabletAlu/Clear PVDC Blister Pack x 10's (Box of 100's)
RxVAT-exempt
Lloyd Laboratories, Inc.Philippines
Watsons Personal Care Stores (Philippines), Inc.Trader: Westfield Pharmaceutical, Inc.
DRP-6965
Apr 3, 2027
NoneClonidine hydrochloride
75 mcg TabletAlu/Clear PVC Blister Pack x 20's (Box of 100’s)
RxVAT-exempt
Sai Parenterals Ltd.TSIIC Industrial Park Hyderabad-Warangal Highway Bhongir Telangana 508116 India
PharmaVital Corp.Importer: Nelpa Lifesciences Inc.
DRP-12495-03
Jul 2, 2030
NoneClonidine hydrochloride
75 mcg TabletAlu/PVC Blister Pack x 20's (Box of 100's)
RxVAT-exempt
Amherst Laboratories, Inc.Philippines
RiteMed Philippines, Inc.Trader: UNILAB, Inc.
DRP-1868-01
Jun 22, 2027
NoneClonidine
75 mcg TabletAlu/Clear PVDC Blister Pack x 10's Box of 100's
RxVAT-exempt
Lloyd Laboratories, Inc.Philippines
Rose Pharmacy, IncorporatedTrader: Innogen Pharmaceuticals, Inc.
DRP-6300-01
Feb 16, 2028
NoneClonidine
75 mcg TabletAlu/Clear PVDC Blister Pack x 10's (Box of 100's)
RxVAT-exempt
Lloyd Laboratories, Inc.Philippines
Actimed, Inc.Trader: Innogen Pharmaceuticals, Inc.
DRP-6300-02
Feb 16, 2028
NoneClonidine
75 mcg TabletAlu/Clear PVDC Blister Pack x 10's (Box of 100's)
RxVAT-exempt
Lloyd Laboratories, Inc.Philippines
South Star DrugTrader: Innogen Pharmaceuticals, Inc.
DRP-6300-03
Feb 16, 2028
NoneClonidine Hydrochloride
75 mcg TabletAlu/PVC Blister Pack x 20's (Box of 100's)
RxVAT-exempt
Drugmaker’s Laboratories Inc.Philippines
TGP Pharma Inc.
DRP-6787-01
Jul 19, 2028
NormipressClonidine hydrochloride
150 mcg TabletAlu/Clear PVDC Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Lloyd Laboratories, Inc.Philippines
Trader: Littman Drug Corporation
DR-XY44226
Feb 23, 2030
TerclodineClonidine (as Hydrochloride)
150 mcg TabletAlu/Clear PVC Blister Pack x 20's (Box of 100's)
RxVAT-exempt
Drugmaker's Laboratories, Inc.Philippines
—
DR-XY40131
Oct 7, 2028
UnbrandedClonidine Hydrochloride
75 mcg TabletClear PVDC/Alu Blister Pack x 10's (Box of 100's)
RxVAT-exempt
Lloyd Laboratories, Inc.Philippines
Foramen Products CorporationTrader: Gamot Philippines, Inc.
DRP-6744-01
Aug 17, 2031
(no brand name)Clonidine Hydrochloride
150mcg TabletAlu/Clear PVC Blister Pack x 20' s (Box 100' s)
RxVAT-exempt
Drugmaker's Laboratories, Inc.Philippines
—
DRP-14144
Jun 30, 2028

Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.

Warnings/Precautions

Warnings and precautions (US label) US FDA label

WARNINGS Withdrawal Patients should be instructed not to discontinue therapy without consulting their physician. Sudden cessation of clonidine treatment has, in some cases, resulted in symptoms such as nervousness, agitation, headache, and tremor accompanied or followed by a rapid rise in blood pressure and elevated catecholamine concentrations in the plasma.

The likelihood of such reactions to discontinuation of clonidine therapy appears to be greater after administration of higher doses or continuation of concomitant beta-blocker treatment and special caution is therefore advised in these situations. Rare instances of hypertensive encephalopathy, cerebrovascular accidents and death have been reported after clonidine withdrawal.

When discontinuing therapy with clonidine hydrochloride, the physician should reduce the dose gradually over 2 to 4 days to avoid withdrawal symptomatology. An excessive rise in blood pressure following discontinuation of clonidine hydrochloride therapy can be reversed by administration of oral clonidine hydrochloride or by intravenous phentolamine.

If therapy is to be discontinued in patients receiving a beta-blocker and clonidine concurrently, the beta-blocker should be withdrawn several days before the gradual discontinuation of clonidine hydrochloride. Because children commonly have gastrointestinal illnesses that lead to vomiting, they may be particularly susceptible to hypertensive episodes resulting from abrupt inability to take medication.

Drug interactions

Drug interactions (US label) US FDA label

Drug Interactions Clonidine may potentiate the CNS-depressive effects of alcohol, barbiturates or other sedating drugs. If a patient receiving clonidine hydrochloride is also taking tricyclic antidepressants, the hypotensive effect of clonidine may be reduced, necessitating an increase in the clonidine dose. If a patient receiving clonidine is also taking neuroleptics, orthostatic regulation disturbances (e.g., orthostatic hypotension, dizziness, fatigue) may be induced or exacerbated.

Monitor heart rate in patients receiving clonidine concomitantly with agents known to affect sinus node function or AV nodal conduction, e.g. digitalis, calcium channel blockers and beta-blockers. Sinus bradycardia resulting in hospitalization and pacemaker insertion has been reported in association with the use of clonidine concomitantly with diltiazem or verapamil.

Amitriptyline in combination with clonidine enhances the manifestation of corneal lesions in rats (see Toxicology). Based on observations in patients in a state of alcoholic delirium it has been suggested that high intravenous doses of clonidine may increase the arrhythmogenic potential (QT-prolongation, ventricular fibrillation) of high intravenous doses of haloperidol.

Causal relationship and relevance for clonidine oral tablets have not been established. Toxicology In several studies with oral clonidine hydrochloride, a dose-dependent increase in the incidence and severity of spontaneous retinal degeneration was seen in albino rats treated for six months or longer. Tissue distribution studies in dogs and monkeys showed a concentration of clonidine in the choroid.

In view of the retinal degeneration seen in rats, eye examinations were performed during clinical trials in 908 patients before, and periodically after, the start of clonidine therapy. In 353 of these 908 patients, the eye examinations were carried out over periods of 24 months or longer. Except for some dryness of the eyes, no drug-related abnormal ophthalmological findings were recorded and, according to specialized tests such as electroretinography and macular dazzle, retinal function was unchanged.

In combination with amitriptyline, clonidine hydrochloride administration led to the development of corneal lesions in rats within 5 days.

Adverse reactions

Adverse reactions (US label) US FDA label

ADVERSE REACTIONS Most adverse effects are mild and tend to diminish with continued therapy. The most frequent (which appear to be dose-related) are dry mouth, occurring in about 40 of 100 patients; drowsiness, about 33 in 100; dizziness, about 16 in 100; constipation and sedation, each about 10 in 100. The following less frequent adverse experiences have also been reported in patients receiving clonidine hydrochloride, but in many cases patients were receiving concomitant medication and a causal relationship has not been established.

Body as a Whole: Fatigue, fever, headache, pallor, weakness, and withdrawal syndrome. Also reported were a weakly positive Coombs’ test and increased sensitivity to alcohol. Cardiovascular: Bradycardia, congestive heart failure, electrocardiographic abnormalities (i.e., sinus node arrest, junctional bradycardia, high degree AV block and arrhythmias), orthostatic symptoms, palpitations, Raynaud’s phenomenon, syncope, and tachycardia.

Cases of sinus bradycardia and atrioventricular block have been reported, both with and without the use of concomitant digitalis. Central Nervous System: Agitation, anxiety, delirium, delusional perception, hallucinations (including visual and auditory), insomnia, mental depression, nervousness, other behavioral changes, paresthesia, restlessness, sleep disorder, and vivid dreams or nightmares.

Dermatological: Alopecia, angioneurotic edema, hives, pruritus, rash, and urticaria. Gastrointestinal: Abdominal pain, anorexia, constipation, hepatitis, malaise, mild transient abnormalities in liver function tests, nausea, parotitis, pseudo-obstruction (including colonic pseudo-obstruction), salivary gland pain, and vomiting.

Genitourinary: Decreased sexual activity, difficulty in micturition, erectile dysfunction, loss of libido, nocturia, and urinary retention. Hematologic: Thrombocytopenia. Metabolic: Gynecomastia, transient elevation of blood glucose or serum creatine phosphokinase, and weight gain. Musculoskeletal: Leg cramps and muscle or joint pain.

Oro-otolaryngeal: Dryness of the nasal mucosa. Ophthalmological: Accommodation disorder, blurred vision, burning of the eyes, decreased lacrimation, and dryness of eyes.

Pregnancy considerations

Pregnancy (US label) US FDA label

Pregnancy Teratogenic Effects: Pregnancy Category C. Reproduction studies performed in rabbits at doses up to approximately 3 times the oral maximum recommended daily human dose (MRDHD) of clonidine hydrochloride USP produced no evidence of a teratogenic or embryotoxic potential in rabbits. In rats, however, doses as low as 1/3 the oral MRDHD (1/15 the MRDHD on a mg/m 2 basis) of clonidine were associated with increased resorptions in a study in which dams were treated continuously from 2 months prior to mating.

Increased resorptions were not associated with treatment at the same time or at higher dose levels (up to 3 times the oral MRDHD) when the dams were treated on gestation days 6 to 15. Increases in resorption were observed at much higher dose levels (40 times the oral MRDHD on a mg/kg basis; 4 to 8 times the MRDHD on a mg/m 2 basis) in mice and rats treated on gestation days 1 to 14 (lowest dose employed in the study was 500 mcg/kg).

No adequate, well-controlled studies have been conducted in pregnant women. Clonidine crosses the placental barrier (see CLINICAL PHARMACOLOGY, Pharmacokinetics). Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.

Breastfeeding considerations

Lactation (US label) US FDA label

Nursing Mothers As clonidine hydrochloride is excreted in human milk, caution should be exercised when clonidine hydrochloride is administered to a nursing woman.

Pharmacokinetics

Half-life and elimination (verbatim, US label)

Other studies in patients have provided evidence of a reduction in plasma renin activity and in the excretion of aldosterone and catecholamines.

Following intravenous administration, clonidine displays biphasic disposition with a distribution half-life of about 20 minutes and an elimination half-life ranging from 12 to 16 hours.

The half-life increases up to 41 hours in patients with severe impairment of renal function.

Pharmacokinetics (US label) US FDA label

CLINICAL PHARMACOLOGY Clonidine stimulates alpha-adrenoreceptors in the brain stem. This action results in reduced sympathetic outflow from the central nervous system and in decreases in peripheral resistance, renal vascular resistance, heart rate, and blood pressure. Clonidine hydrochloride acts relatively rapidly. The patient’s blood pressure declines within 30 to 60 minutes after an oral dose, the maximum decrease occurring within 2 to 4 hours.

Renal blood flow and glomerular filtration rate remain essentially unchanged. Normal postural reflexes are intact; therefore, orthostatic symptoms are mild and infrequent. Acute studies with clonidine hydrochloride in humans have demonstrated a moderate reduction (15% to 20%) of cardiac output in the supine position with no change in the peripheral resistance: at a 45° tilt there is a smaller reduction in cardiac output and a decrease of peripheral resistance.

During long term therapy, cardiac output tends to return to control values, while peripheral resistance remains decreased. Slowing of the pulse rate has been observed in most patients given clonidine, but the drug does not alter normal hemodynamic response to exercise. Tolerance to the antihypertensive effect may develop in some patients, necessitating a reevaluation of therapy.

Other studies in patients have provided evidence of a reduction in plasma renin activity and in the excretion of aldosterone and catecholamines. The exact relationship of these pharmacologic actions to the antihypertensive effect of clonidine has not been fully elucidated. Clonidine acutely stimulates growth hormone release in both children and adults, but does not produce a chronic elevation of growth hormone with long-term use.

Pharmacokinetics The pharmacokinetics of clonidine is dose-proportional in the range of 100 to 600 mcg. The absolute bioavailability of clonidine on oral administration is 70% to 80%. Peak plasma clonidine levels are attained in approximately 1 to 3 hours. Following intravenous administration, clonidine displays biphasic disposition with a distribution half-life of about 20 minutes and an elimination half-life ranging from 12 to 16 hours.

The half-life increases up to 41 hours in patients with severe impairment of renal function. Clonidine crosses the placental barrier. It has been shown to cross the blood-brain barrier in rats. Following oral administration about 40% to 60% of the absorbed dose is recovered in the urine as unchanged drug in 24 hours. About 50% of the absorbed dose is metabolized in the liver.

Neither food nor the race of the patient influences the pharmacokinetics of clonidine. The antihypertensive effect is reached at plasma concentrations between about 0.2 and 2.0 ng/mL in patients with normal excretory function. A further rise in the plasma levels will not enhance the antihypertensive effect.

Formulary and pricing (Philippines)

Government price references

PreparationPrice (PHP)UnitType
Clonidine 75 mcg Tablet₱3.89–₱16.50Reference ₱4.95per tabletDPRI procurement range
Clonidine 150 mcg Tablet₱4.25–₱40.19Reference ₱11.00per tabletDPRI procurement range
Clonidine 150 mcg/mL, 1 mL Ampule₱40.19–₱110.90Reference ₱92.44per ampuleDPRI procurement range
75 mcg (as hydrochloride) tablet₱16.50per tabletPhilHealth GAMOT fixed fee
150 mcg (as hydrochloride) tablet₱21.50per tabletPhilHealth GAMOT fixed fee

PhilHealth GAMOT fixed fee paid to the accredited GAMOT pharmacy per unit dispensed Range = lowest-highest procurement price (highest usable only in GIDA areas); reference_price = 2021 DPRI ceiling (median)

These are government procurement and reimbursement references, not retail prices. Sources:

Formulary and coverage

Philippine National FormularyListed as Clonidine
PNF listingOral: 75 micrograms and 150 micrograms tablet (as hydrochloride)
PNF listingInj.: 150 micrograms/mL, 1 mL ampul (IV) (as hydrochloride)
PhilHealth GAMOTYes (listed since July 28, 2025)

Sources:

Check availability

Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.

References

  1. U.S. Food and Drug Administration. clonidine hydrochloride · Alembic Pharmaceuticals Limited [US FDA-approved label, version 5, September 30, 2026]. Via DailyMed/openFDA. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=88a8db46-0fc9-48cd-b7cc-ac9c9cdea100
  2. Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph
  3. PNF Essential Medicines List, 8th ed. (as of November 2, 2022), DOH; https://www.philhealth.gov.ph/partners/providers/pdf/PNF-EML_11022022.pdf
  4. PhilHealth Circular No. 2026-0018, Expanding Access to Outpatient First-line Anti-TB Drugs through PhilHealth GAMOT, Annex A.i GAMOT List (81 molecules); https://www.philhealth.gov.ph/circulars/2026/PC-2026-0018.pdf
  5. PhilHealth Circular No. 2026-0018, Annex A.2 GAMOT Fixed Fee Schedule (249 preparations; fees otherwise unchanged from PC2025-0013); https://www.philhealth.gov.ph/circulars/2026/PC-2026-0018.pdf
  6. DOH Drug Price Reference Index (DPRI) 2021, 9th edition (as of September 17, 2021); https://caro.doh.gov.ph/wp-content/uploads/2021/09/2021DPRI-as-of-9-17-2021.pdf

This page shows official label and registry text only; no renalcarematters.com clinical summary has been approved for it yet.

For health professionals. This page is a reference compiled from public regulatory sources for licensed health professionals in the Philippines. Verify every product detail against the current Philippine package insert and the FDA Philippines registration record. Information here is not a substitute for clinical judgment and does not replace the prescribing information approved for the specific product you dispense or prescribe.

Last updated: .